I've posted my strategy before. I have just common shares. I've sold some already and will end up selling 20% of my holding before data comes out. I will leave the rest fully exposed to what I think will be good data.

I will roll the proceeds from MNKD into several stocks, including ARWR (phase 1 data in Hep B in Q4), XOMA (running a bunch of trials for a drug for inflammation), ASTX (presenting phase 2 data for second-generation version of Dacogen at ASH on December 7), SGYP (running trials in chronic constipation and irritable bowel syndrome) and ACRX (filing NDA this quarter for their Sufentanil delivery system).

Hope this helps.